MOREPENLAB
vs
B
BSE Sensex 30
MOREPENLAB
Over the past 12 months, MOREPENLAB has underperformed BSE Sensex 30, delivering a return of -17% compared to the BSE Sensex 30's +5% growth.
Stocks Performance
MOREPENLAB vs BSE Sensex 30
Performance Gap
MOREPENLAB vs BSE Sensex 30
Performance By Year
MOREPENLAB vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Morepen Laboratories Ltd
Glance View
Morepen Laboratories Ltd. engages in the manufacture and market of bulk drugs and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi. The firm is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also the home health products. Its APIs include Apixaban, Edoxaban, Sitagliptin, Linagliptin, Empagliflozin, Atorvastatin, Loratadine, Desloratadine, Montelukast Sodium, Atorvastatin Calcium, Fexofenadine, Sitagliptin Phosphate, Vildagliptin and Rivaroxaban, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier With HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited and Total Care Limited, among others.
